NEW YORK (GenomeWeb) – Pressure BioSciences said on Thursday that it has engaged investment bank IssuWorks to review strategic and financing alternatives, including the potential spin off of "vertical market applications into new, stand-alone businesses."

In a statement, Pressure Bio CEO Richard Schumacher said that with the help of IssuWorks, "we will immediately begin to look at various … alternatives that we believe have the potential to result in the generation of increased value for all shareholders of" the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."